MXPA05002561A - Nuevas formulaciones de liberacion prolongada inyectables. - Google Patents

Nuevas formulaciones de liberacion prolongada inyectables.

Info

Publication number
MXPA05002561A
MXPA05002561A MXPA05002561A MXPA05002561A MXPA05002561A MX PA05002561 A MXPA05002561 A MX PA05002561A MX PA05002561 A MXPA05002561 A MX PA05002561A MX PA05002561 A MXPA05002561 A MX PA05002561A MX PA05002561 A MXPA05002561 A MX PA05002561A
Authority
MX
Mexico
Prior art keywords
ziprasidone
release formulation
sbecd
cyclodextrin
injectable
Prior art date
Application number
MXPA05002561A
Other languages
English (en)
Spanish (es)
Inventor
Jaymin Chandrakant Shah
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA05002561A publication Critical patent/MXPA05002561A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
MXPA05002561A 2002-10-25 2003-10-13 Nuevas formulaciones de liberacion prolongada inyectables. MXPA05002561A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42147302P 2002-10-25 2002-10-25
PCT/IB2003/004576 WO2004037289A2 (en) 2002-10-25 2003-10-13 Novel injectable depot formulations

Publications (1)

Publication Number Publication Date
MXPA05002561A true MXPA05002561A (es) 2005-05-05

Family

ID=32176718

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05002561A MXPA05002561A (es) 2002-10-25 2003-10-13 Nuevas formulaciones de liberacion prolongada inyectables.

Country Status (20)

Country Link
US (1) US20040138237A1 (https=)
EP (1) EP1575616A2 (https=)
JP (1) JP2006514923A (https=)
KR (1) KR20050055781A (https=)
CN (1) CN1849110A (https=)
AR (1) AR041722A1 (https=)
AU (1) AU2003267788A1 (https=)
BR (1) BR0315568A (https=)
CA (1) CA2503076A1 (https=)
MX (1) MXPA05002561A (https=)
NL (1) NL1024590C2 (https=)
NO (1) NO20052463L (https=)
PA (1) PA8586201A1 (https=)
PE (1) PE20040499A1 (https=)
PL (1) PL377679A1 (https=)
RU (1) RU2310450C2 (https=)
TW (1) TW200423941A (https=)
UY (1) UY28038A1 (https=)
WO (1) WO2004037289A2 (https=)
ZA (1) ZA200501921B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
KR20090080143A (ko) * 2003-09-02 2009-07-23 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
SI2415484T1 (sl) * 2004-09-17 2014-10-30 Durect Corporation Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
CA2598288A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
CA2603189A1 (en) * 2005-04-13 2006-10-19 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
CN101166514A (zh) * 2005-04-13 2008-04-23 辉瑞产品公司 用于提供持续释放的纳米粒组合物的可注射储库制剂及方法
CA2613474A1 (en) * 2005-06-20 2007-03-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
KR100908517B1 (ko) * 2006-07-04 2009-07-20 (주)아모레퍼시픽 호흡기계 약제 전달을 위한 서방형 다공성 미세입자 및 그제조 방법
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
JP2011506319A (ja) * 2007-12-06 2011-03-03 デュレクト コーポレーション 疼痛、関節炎症状、または慢性疾患に伴う炎症の治療に有用な方法
JP5643195B2 (ja) * 2008-06-16 2014-12-17 デビオファーム インターナショナル ソシエテ アノニム 濃縮オキサリプラチン溶液及びその調製方法
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
AU2014233453A1 (en) 2013-03-15 2015-10-01 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CN104688686A (zh) * 2015-02-10 2015-06-10 万全万特制药江苏有限公司 一种含有齐拉西酮及其盐的脂肪乳注射剂
US12274794B2 (en) 2016-07-06 2025-04-15 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
WO2018015915A1 (en) * 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
AU2019250128A1 (en) 2018-10-15 2020-04-30 Avent Inc. Compositions, systems, kits, and methods for neural ablation
JP2023515918A (ja) 2020-01-13 2023-04-17 デュレクト コーポレーション 不純物が低減された徐放性薬物送達システム及び関連の方法
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029782A (en) * 1975-04-28 1977-06-14 Eli Lilly And Company Cefazolin suspension for parenteral administration
US4512986A (en) * 1983-07-26 1985-04-23 Research Triangle Institute Progrestationally active steroids
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
ATE203157T1 (de) * 1996-12-20 2001-08-15 Alza Corp Injizierbare depotgelzubereitung und herstellungsverfahren
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
DE1073432T1 (de) * 1998-04-14 2002-02-07 The General Hospital Corp., Boston Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden
ES2191618T3 (es) * 1999-05-27 2003-09-16 Pfizer Prod Inc Suspension de ziprasidona.
US6753011B2 (en) * 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
JP4334229B2 (ja) * 2001-03-20 2009-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers

Also Published As

Publication number Publication date
ZA200501921B (en) 2006-10-25
WO2004037289A2 (en) 2004-05-06
US20040138237A1 (en) 2004-07-15
CA2503076A1 (en) 2004-05-06
BR0315568A (pt) 2005-08-23
JP2006514923A (ja) 2006-05-18
EP1575616A2 (en) 2005-09-21
TW200423941A (en) 2004-11-16
UY28038A1 (es) 2004-05-31
AR041722A1 (es) 2005-05-26
PE20040499A1 (es) 2004-08-18
RU2005112207A (ru) 2005-09-10
RU2310450C2 (ru) 2007-11-20
NL1024590C2 (nl) 2005-05-23
NL1024590A1 (nl) 2004-04-27
KR20050055781A (ko) 2005-06-13
NO20052463L (no) 2005-05-23
AU2003267788A1 (en) 2004-05-13
PL377679A1 (pl) 2006-02-06
WO2004037289A3 (en) 2005-12-01
PA8586201A1 (es) 2004-09-16
CN1849110A (zh) 2006-10-18

Similar Documents

Publication Publication Date Title
MXPA05002561A (es) Nuevas formulaciones de liberacion prolongada inyectables.
JP5565794B2 (ja) ピモベンダン及びシクロデキストリンの錯体を含む液体製剤
JP6461945B2 (ja) ある含有量のマイトマイシンｃを有する凍結乾燥医薬組成物を製造する方法
NL1024616C (nl) Depotpreparaten in de vorm van een suspensie.
US20190365720A1 (en) Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
JP6818019B2 (ja) レファムリンの注射可能医薬組成物
US20070049552A1 (en) Fluoroquinolone formulations and methods of making and using the same
US20120283304A1 (en) Formulations of Temozolomide for Parenteral Administration
EP3013316B1 (en) Stable intravenous formulation
WO2001087262A2 (en) Stabilized steroidal suspension
HK1092054A (en) Novel injectable depot formulations
WO2011101865A2 (en) Stable pharmaceutical compositions of clopidogrel for parenteral delivery
HK1084321A (en) Depot formulations of arylheterocyclic active agents in the form of a suspension